Clinical trial

Gene therapy shows promise in Parkinson’s disease

2100 1400 Mea Holm, PhD

Interim results from a Phase Ib trial show that gene therapy may reduce the need for medication in patients with Parkinson’s disease refractory to levodopa. The investigational therapy is designed…

read more

Serum neurofilament light: A biomarker for disease activity in MS

1920 1080 Mea Holm, PhD

How close are we to establishing a reliable liquid biomarker for detecting disease onset, progression and treatment response in multiple sclerosis? According to Dr Peter Calabresi (Johns Hopkins, USA) at…

read more

Results from the MS-SMART trial unveiled

3971 2975 Mea Holm, PhD

Secondary progressive multiple sclerosis (SPMS) is known to be extremely difficult to treat; there are no effective therapies for halting or reversing disability progression in the late disease phase. In…

read more

FLOODLIGHT offers illuminating outcomes for smartphone monitoring in MS

1920 1080 Peter Stevenson, PhD

Smartphone-based, high-yield active and passive self-monitoring of multiple sclerosis (MS) may enhance clinical disease assessments when compared to conventional methods for detecting subtle progressive clinical changes, according to a study…

read more

Restoring “conductor” cells in the orchestra of schizophrenia

2850 1900 Peter Stevenson, PhD

Key symptoms of schizophrenia, including hallucinations, hyperactivity and impaired memory, could be caused by desynchronised cells in the brain, recent research published in Nature Neuroscience has revealed. The authors investigated…

read more

Quarterly migraine injection approved in US

2885 1900 Peter Stevenson, PhD

The US FDA has approved a new humanised monoclonal antibody for migraine prevention in adults. Fremanezumab-vfrm – under the brand name AJOVYTM (Teva Pharmaceuticals) – prevents the interaction between calcitonin…

read more

Opticians could keep a closer eye on dementia

2704 1800 Peter Stevenson, PhD

Routine retinal tests performed by opticians could help to identify those at risk of developing dementia, a new study reports. The scans – normally used to evaluate the integrity of…

read more

Deep brain stimulation effective in early Parkinson’s tremors

1600 1067 Peter Stevenson, PhD

Deep brain stimulation (DBS) could slow the progression of tremors in Parkinson’s disease (PD), according to new data from a pilot trial.1 Researchers at the Vanderbilt University Medical Center (Nashville,…

read more

Rasagiline add-on treatment may offer hope to fast-progressing ALS patients

8001 4501 Mea Holm, PhD

At the ‘late breaking’ session of the EAN 2018 congress, Professor Albert Ludolph from Ulm University (Germany) unveiled the results of a recent double-blind, randomised Phase II trial of rasagiline…

read more

Revolutionary therapies could make spinal muscular atrophy a distant memory

1200 675 Peter Stevenson, PhD

Cutting-edge molecular and genetic therapies for neurogenic disorders took centre stage at the EAN congress, with novel therapies showcased for the treatment of spinal muscular atrophy (SMA) – a severe…

read more
Brainwork is supported by unrestricted grants from: